LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned an average recommendation of “Moderate Buy” from the nine research firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $94.57.

LMAT has been the topic of several analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. Barrington Research upped their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Lake Street Capital assumed coverage on LeMaitre Vascular in a research note on Friday, August 2nd. They issued a “buy” rating and a $105.00 target price on the stock. Finally, JMP Securities boosted their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th.

LeMaitre Vascular Stock Up 0.4 %

NASDAQ LMAT opened at $105.80 on Thursday. The company has a 50-day simple moving average of $94.86 and a two-hundred day simple moving average of $87.55. LeMaitre Vascular has a 12-month low of $51.70 and a 12-month high of $109.58. The firm has a market cap of $2.38 billion, a price-to-earnings ratio of 57.81, a PEG ratio of 2.62 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. The company had revenue of $54.82 million during the quarter, compared to analysts’ expectations of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. LeMaitre Vascular’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.33 EPS. Equities analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be issued a $0.16 dividend. The ex-dividend date of this dividend is Thursday, November 21st. This represents a $0.64 annualized dividend and a yield of 0.60%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.97%.

Insider Buying and Selling at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the transaction, the director now directly owns 2,278 shares in the company, valued at $231,148.66. This trade represents a 62.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 10.79% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. NBC Securities Inc. grew its stake in shares of LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 183 shares during the last quarter. GAMMA Investing LLC boosted its stake in LeMaitre Vascular by 57.0% in the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after purchasing an additional 199 shares in the last quarter. USA Financial Formulas bought a new position in LeMaitre Vascular in the 3rd quarter worth about $60,000. West Oak Capital LLC purchased a new stake in LeMaitre Vascular during the 2nd quarter valued at about $58,000. Finally, nVerses Capital LLC increased its stake in LeMaitre Vascular by 33.3% during the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after purchasing an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.